Follicular lymphoma is a slow-growing type of blood cancer involving the lymph nodes. It is the most common type of slow-growing lymphoma, and is more commonly diagnosed in people older than 60, but adults of any age can be affected. Swollen lymph nodes are often the first sign. Follicular lymphoma cannot be completely cured but treatment is available that allows many people to have a normal lifespan and a good quality of life.

'Fast Facts: Follicular Lymphoma' provides an introduction to follicular lymphoma for healthcare professionals and others with an interest in this blood cancer. It summarizes what is known about the pathophysiology of the disease, and discusses the importance of accurate diagnosis, classification, and risk assessment, together with existing approaches to treatment and monitoring. Looking into the future, it also reviews some of the therapies in development, which may ultimately improve quality of life and ensure better outcomes for patients with FL.

For nearly 25 years, Ferri's concise, pocket-sized resource has served as the go-to reference for practical, clinical information among students, residents, and other medical professionals. Formerly known as Practical Guide to the Care of the Medical Patient, this volume continues to provide a fast, effective, and efficient way to identify the important clinical, laboratory, and diagnostic imaging information you need to get through your internal medicine clerkship or residency. - Consult this title on your favorite device, conduct rapid searches, and adjust font sizes for optimal readability. - Benefit from the expert guidance of Dr. Fred Ferri, a leading teacher, clinician, and author. - Confidently manage patients with the latest clinical information, drug therapies, and lab tests. - Apply the latest knowledge and techniques with this updated and streamlined title, which still stays true to the Ferri name. - Quickly find important information with content organized into three major sections: Section I, titled "Surviving the Wards," contains information on charting, laboratory evaluation and formulary; Section II provides the differential diagnosis of common signs and symptoms likely to be encountered in the acute care setting; Section III has been completely revised and subdivided into 11 specialty specific diseases and disorders. - Carry just the sections you need, add personalized materials, and keep everything together and safe with an improved ring binder and design. - Access the full text and procedural videos online at Expert Consult.

Lymphoma can be broadly defined as a cancer of mature lymphocytes. Our understanding of the biology of normal lymphocytes and lymphoma has grown at a tremendous pace, and this is now directly translating into changes in clinical practice. This became evident with the introduction of one of the first therapeutic monoclonal antibodies into cancer medicine, the CD20-directed antibody rituximab, which has led to significant benefit for patients with B-cell lymphomas. Since then, a raft of novel agents has entered clinical practice, including targeted small molecules, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells. This new edition of 'Fast Facts: Lymphoma' has been updated to include recent changes in our understanding of lymphoma biology as well as improvements in diagnostics and therapeutics.

The tyrosine kinase inhibitor (TKI) imatinib was the first treatment to specifically target cancer cells, rather than the relatively indiscriminate effects of conventional chemotherapy on any rapidly dividing cells. This concept of targeted treatment in cancer is one of the important advances in modern medicine in the last 30 years. Indeed, treatment with TKIs has transformed chronic myeloid leukemia (CML) from a cancer with a poor prognosis to one in which many patients can expect a normal lifespan. Success with the TKIs has prompted the question of whether it is desirable – or feasible – for patients to remain on treatment for long periods. While the TKIs are targeted, they are associated with considerable toxicity, and long-term treatment has important economic implications for health services and patients. Thus, the concept of treatment-free remission (TFR) has emerged for patients in deep clinical remission. Clinical research over the last decade has focused on whether treatment can be stopped, how to best monitor patients while off treatment, and how to intervene before a clinical relapse. As this research progresses, the tantalizing prospect of a cure for some patients seems increasingly feasible. This new Fast Facts title outlines this trail-blazing approach to the long-term management of patients living with CML in remission. It explains the concepts of molecular and hematologic relapse, the highly sensitive technologies that allow disease monitoring, and how TFR is best managed in practice. It is a concise educational resource, ideal for any healthcare professional involved in the treatment of patients with CML who wants to understand TFR, particularly clinical nurse specialists and pharmacists who increasingly help clinicians to run CML clinics. Table of Contents: • The concept of treatment-free remission • Measurement of disease burden • Clinical practice • Future directions

Written by leading experts, 'Fast Facts: Clinical Trials in Oncology' will enhance the reader’s ability to critically evaluate published evidence. Assuming little or no prior knowledge, the book sets out clearly the fundamental features of clinical trials. The key attributes of Phase I–III trials of pharmaceutical products are described, as are trials of surgical procedures, radiation therapy and advanced therapies. The processes and documentation required to set up and conduct a trial are outlined, and the authors describe how trial data and real-world evidence are used to improve care. Although this concise colorful book focuses on oncology, the principles apply equally to interventions in other areas of practice. It will prove invaluable to medical, pharmaceutical and allied health professionals who want, or need, an overview of how contemporary clinical trials are designed and conducted. Contents: • Fundamental features of clinical trials • Phase I trials • Phase II trials • Phase III trials • Trials of non-drug interventions • Setting up and conducting trials • Publishing trial results, changing clinical practice, and supporting evidence

Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Fast Facts: Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. Contents: • Biologics and the need for biosimilars • Why do we need biosimilars? • How is the quality of biosimilar medicines assured? • Legal issues • Switching, interchangeability and extrapolation • Safety and pharmacovigilant • Global issues • Formulary considerations: pharmacy issues • Formulary considerations: supportive care biosimilars • Formulary considerations: therapeutic anti-cancer biosimilars • Communication and awareness